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ABSTRACT
Background: There is no consensus regarding the
treatment of Achilles insertional tendinopathies.
Eccentric training remains the main choice in the
conservative treatment of this illness; however, the
good results in the management of non-insertional
Achilles tendinopathy were not replicated in the
insertional condition. Low energy shock wave therapy
has been described as an alternative to these patients,
but has yet to be empirically tested.
Hypothesis: Shock wave therapy, adjunctive to the
eccentric strengthening protocol, will improve
measures of pain and function.
Design: Double blind, placebo-controlled, parallel
groups, randomised clinical trial.
Materials and methods: 93 patients with a
diagnosis of chronic insertional tendinopathy, referred
from primary or secondary healthcare services, will be
assessed and enrolled in this study. They will be
divided into two groups (randomised by sequentially
numbered identical envelopes, which will be
administered serially to participants), one containing
the combination of low energy shock wave and
eccentric exercises, as treatment and the other
comprehending the exercises and the placebo
treatment (an apparatus placed in the therapeutic
head). The assessments will occur in 2, 4, 6, 12 and
24 weeks. Patients will be evaluated primarily by the
Victorian Institute of Sport Assessment-Achilles
questionnaire and secondarily by the visual analogue
scale, Algometry, the American Orthopedic Foot and
Ankle Society scale, the Foot and Ankle Outcome Score
and the 12-item Short Form Health Survey. We will use
comparison of two proportions via relative frequency
analysis, the Pearson Correlation the χ2 test and the
analysis of variance for statistical analyses.
Discussion: This study intends to demonstrate if the
association of the eccentric exercise programme with the
shock wave therapy can produce good results regarding
the treatment of the Achilles insertional tendinopathy. In
an attempt to prevent the high costs and complications
associated with the surgical intervention, we will try to
prove this combination as a viable therapeutic option in
the conservative management of this prevalent condition.
The strengths of the study are the design and the novelty
of the combination of methods. The main limitation is the
short follow-up course.
Ethics and dissemination: The study is registered in
the Clinical Trials database (protocol number:
8094833648737701) and was approved by the University
Ethics Committee (number: 1373481).
Trial registration number: 8094833648737701
(NCT02757664); Pre-results.
INTRODUCTION
Calcaneus tendinopathy can be classified
according to its anatomic site, as insertional
and non-insertional tendinopathy. It is char-
acterised by intratendinous degenerations,
Strengths and limitations of this study
▪ Study design is ideal for treatment
recommendations.
▪ Combination of methods novelty.
▪ Previous sample size calculation.
▪ Double-blinded design minimising benchmarking
bias.
▪ Previous protocol publication minimising publi-
cation bias.
▪ Short follow-up course limiting the cross-check
of long-term effects and complications.
▪ Single-centre study decreasing
external validation.
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secondary to low grade inflammatory signs and erratic
biological healing.1–3 Insertional tendinopathy occurs in
the Achilles attachment to the tuberosity of the calca-
neus bone and up to 2 cm proximal to the tuberosity. It
is generally associated with a traction enthesophyte
(upper spur), Haglund deformity (pump bump) and with
preAchilles bursitis and retroAchilles bursitis. The diag-
nosis is made based on clinical evaluation; ancillary tests,
such as X-ray and ultrasound, are performed only to
confirm the lesion and to exclude differential diagnoses
(stress fractures, tumours). The clinical diagnosis con-
sists of checking the level of pain via palpation of the
tendinous insertion region in the calcaneus bone (and
up to 2 cm around this region). The occurrence of
volume increase and mild hyperaemia also supports the
diagnosis.1–4
Historically, the condition’s initial treatment is based
on eccentric strengthening of the tendon. Results for
non-insertional tendinopathy are encouraging, with an
82% success rate when analysing return to previous activ-
ities.5 6 However, evidence indicates that eccentric
strengthening for insertional tendinopathy produced a
rate of improvement ranging between 32% and 67% of
the patients.2–4 Within this context, shock wave therapy
has been proposed as a viable option, in case of failure
of the conservative treatment and prior to referral
to surgery.7–9 Over the past 30 years, extracorporeal
shock waves have been safely and efficiently used in the
treatment of various pathological conditions.10 11
Extracorporeal shock wave lithotripsy (ESWL), for
example, is a well-established treatment for urological
pathologies. More recently, low12–14 and high14 15 energy
shock wave therapies are being used in the treatment of
pseudoarthrosis16 17 and several types of tendinopathy
with prominent results.18–21
Accumulating evidence indicates that the use of shock
waves induces neovascularisation and release of angio-
genic markers by the recruitment of mesenchymal stem
cells.12 13 22 The molecular mechanism explaining how
the shock wave produces these consequences is yet to be
determined.15 17 Neovascularisation improves blood irri-
gation, which, in its turn, contributes to tissue regener-
ation in the tendon-bone junction. Separate lines of
inquiry suggested that shock wave therapy, relative to
placebo therapies, induces a higher increase of mechan-
ical resistance and concentration of markers of collagen
synthesis (ie, hydroxiproline and pyridinoline), which are
important components of the healing process.12 14 16
Clinically, few complications are associated with shock
waves, with transient regional hyperemia being the most
frequently reported. Few patients (5%) report having
pain after high energy shock wave application, which nor-
mally ceases at the end of the treatment.8 Tendon
rupture was described in the literature in only 1 study,23
which showed 2 cases of older patients in a population of
49 cases. The authors could not find a true relation
between the therapy and the events. Rasmussem et al24
have carried out a randomised clinical trial with 48
patients and 12 months of follow-up, comparing the use
of radial shock wave therapy in patients after 4 weeks of
conservative treatment, including stretching and
strengthening, with the placebo. Superior results regard-
ing pain and function were shown in the group that
received the intervention. Kearney et al4 did a systematic
review of the literature, looking for evidences concerning
the calcaneus insertional tendinopathy treatment. They
found only one paper8 with the usage of the high energy
therapy, but, nevertheless, the work was criticised by the
small sample and the methodology inconsistencies.
Shock wave therapy has been progressively more
studied. Recent evidence has indicated that this tech-
nique is a promising option for the management of
chronic insertional tendinopathy; however, the evidence
is still insufficient to inform a consensus regarding the
indication of this treatment in this very frequent condi-
tion.9 19 25 Our objective is to evaluate the effectiveness
of low energy shock wave therapy associated with an
eccentric strengthening protocol, and compare it to
eccentric strengthening associated with placebo, using
the function by the Victorian Institute of Sports
Assessment-Achilles (VISA-A). The primary hypothesis is
that adjunctive shock wave therapy will mitigate pain
and improve function as compared to placebo.
MATERIAL AND METHOD
Design, setting and recruitment
This will be a double blind, placebo-controlled, parallel
groups, randomised clinical trial (figure 1). The study
will be conducted at Hospital São Paulo, a tertiary teach-
ing hospital fully affiliated with the Universidade Federal
de São Paulo (UNIFESP), in the Orthopedics and
Traumatology Department (DOT) at the Centre of
Tissue Research and Regeneration (CPRT).
Participants will be enrolled at the CPRT, which pro-
vides assessment and treatment to ∼10 new patients with
chronic insertional tendinopathy per week. They will be
referred by local orthopaedist doctors or health profes-
sionals. Information to these physicians will be delivered
by email addressed directly to them, as well as via
posters exhibited in places containing orthopaedic
medical care (outpatient clinic, emergency room).
Inclusion criteria
▸ Individuals must be older than 18 and younger than
65 years of age, both genders;
▸ Participants must be experiencing pain symptoms in
the calcaneus tendon insertion region over the past
3 months;
▸ Clinical diagnosis of chronic insertional tendinopathy,
defined as presence of pain at palpation of the ten-
dinous insertion region in the calcaneus bone (and
up to 2 cm around this region); and the occurrence
of increased regional volume, associated with findings
of tendinopathy in the ultrasound scan.
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Figure 1 Flow_Achilles Project submitted to government funding (CNPq (Conselho Nacional de Pesquisa—National Research
Council under the protocol number 8094833648737701)).
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Exclusion criteria
▸ Previous surgery involving the affected foot or ankle;
▸ History or documented evidence of autoimmune or
peripheral vascular diseases;
▸ History or documented evidence of peripheral neur-
opathy (nervous compression syndrome, tarsal tunnel
syndrome) or systemic inflammatory disease (rheuma-
toid arthritis, spondylitis, Reiter syndrome, etc);
▸ Non-insertional or mixed tendinopathy (insertional
and non-insertional);
▸ Previous infiltration in the affected tendon over the
6 months preceding the initial assessment;
▸ Beginning of the present pain, due to a trauma;
▸ Pregnancy;
▸ Any condition that represents a contraindication of
the proposed therapies;
▸ Impossibility or incapacity to sign the informed
consent form;
▸ History or documented evidence of blood coagula-
tion disorders (including treatment with anticoagu-
lants, but excluding aspirin);
▸ Use of heart pacemaker;
▸ Presence of infectious process (superficial on skin
and cellular tissue, or deep in the bone) in the
region to be treated;
Sampling
The sampling calculation is based on the studies of
Rompe et al21 and Sayana et al;6 and considers an esti-
mated effect size of 3.3, a SD of 16.2 and sampling error
of 5%. It was calculated considering 93 patients divided
into 2 groups in a randomised way, estimating that 41
evaluable participants per treatment arm will have better
than 80% power to detect a difference in results
between the shock wave and the placebo participants at
a level of 5% significance. Since we expected a 10% loss
in the follow-up, based on other clinical studies, we plan
to include an extra 10% of participants, totalling 51
patients per group.
Procedures
A written, signed and dated informed consent will be
obtained from the participant before any study-related
procedures are performed. The patients will have to fill
out an initial questionnaire in order to be enrolled
(Attachment 1). After that, the assistant doctor will do
the physical diagnostic examination. Then ultrasound
and X-ray procedures will take place, in order to com-
plete the diagnostic assessment. The patient will be
included in the protocol and duly randomised after the
diagnostic confirmation via anamnesis and physical
examination, and also after completion of supplemen-
tary tests, as well as fulfilment of all the inclusion criteria
and non-adequacy to the exclusion criteria.
The randomisation sequence will be generated via
computing software (http://www.randomizer.org/form.
htm), producing a list from 1–x, and each number will
be related to a sole treatment method. We will do a
randomisation with interchanged blocks, with the same
number of patients in each group.
Each non-transparent, opaque, sealed envelope, num-
bered from 1 to 104, will contain either a paper with the
word ‘physiotherapy’ or with the words ‘physiotherapy
and shock wave’. Each treatment method will have the
same number of envelopes. The patients will be initially
assessed individually, being randomised and allocated in
the same way. The intervention procedures will be the
same, with the same positioning and preparations, but
differing regarding the existence of a support at the
applicator head of the shock wave apparatus in the
group of patients without shock wave.
Neither the patient nor the evaluator doctor will have
access to the protocol test applied to each patient, and
the shock wave (or the placebo) will be conducted by a
different physician. The patients in the placebo group
will receive an apparatus’ therapeutic head with the
support that impedes the shock wave propagation dir-
ectly on the appliance field. This will prevent the inser-
tional region from receive any healing stimulus. Patients
will still be able to hear the equipment’s shock wave
noise and feel the tremble provoked by the machine in
contact with the heel.
Intervention
Usage of shock waves
1. Period from diagnosis to intervention: up to 1 week.
2. The patient will be lying on the stretcher in the
supine position; barefooted, with ear muffs, the feet
towards the shock wave apparatus.
3. The procedure region will be marked with ink
(tendon insertion: the point with the highest local
bulging or the penultimate transversal crease of the
skin in the region).
4. Ultrasound gel will be applied on the region that will
receive the shock wave;
5. Radial shock waves will be applied with a BLT600
equipment (BTL Medical Technologies—Canada),
the intensity being 2000–3000 pulses, 7–10 Hz of fre-
quency, and 1,5 a 2,5Bar of intensity per application.
6. Shock waves will be applied on the first day of treat-
ment (D0) as described above, then repeated on the
second week after the first intervention (2nd week)
and 4 weeks after the first intervention (4th week).
Group without shock wave
1. Period from diagnosis to intervention: up to 1 week.
2. Patient lying on the stretcher in the supine position;
barefooted, with ear muffs, the feet towards the
shock wave apparatus.
3. Localisation of the procedure region, marking it with
ink (tendon insertion: the point with the highest
local bulging or the second last transversal crease of
the skin in the region).
4. Appliance of US gel on the region that will receive
the shock wave;
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5. Placing of the apparatus’ therapeutic head with the
support that impedes the shock wave propagation dir-
ectly on the appliance field.
6. Appliance of radial shock waves with the BLT600
equipment (BTL Medical Technologies—Canada),
the intensity being 2000–3000 pulses, 7–10Hz of fre-
quency, and 1,5 a 2,5Bar of intensity per application.
7. Appliance on the first day of treatment (D0) as
described above, repeated on the second week after
the first intervention (2nd week) and 4 weeks after
the first intervention (4th week).
Eccentric exercises
The groups will be submitted to the Alfredson eccentric
strengthening protocol26–28 for 12 weeks, starting on the
same day of the first appliance. The exercises will be
shown to the patients by the assistant doctor, and a
booklet (Attachment 2) will be handed out, with
detailed explanation concerning the protocol to be fol-
lowed. The patient will practise the exercises standing
on ground level, starting from a flexed ankle position
(tiptoes). Participants will do exercises of passive ankle
extension (dorsiflexion), 3 series of 15 repetitions, with
the knee stretched and 3 series of 15 repetitions with
the knee flexed at 20°. The eccentric stage (downwards)
of the movement will be carried out slowly, while the
patient contracts the muscles and increases the distance
between the attachment and insertion points. This must
be performed only with the affected member, until its
heel reaches the terrain level. The concentric stage
(upwards) will be carried out only with the non-affected
member. In case the pathology involves two members,
the patient will use the upper members to help the prac-
tice in the concentric stage. The patients will be encour-
aged to increase the load with 5 kg load weights placed
in a backpack which the patient will wear to practise the
exercise. The load is increased gradually as long as the
exercise is painless to the patient. The objective’s fulfil-
ment and the quality of the exercise are indicated by the
discomfort felt on that region after the performance of
the series.
The patients cannot perform their base sports activ-
ities during the first 8 weeks of training. After the fourth
week, they will be free to run on a flat incline, as well as
to do biking and water activities that do not generate
painful symptoms. After the eighth week, they will be
permitted to gradually restart the sports activities that
they used to perform previously, as long as they are not
feeling any pain. The strengthening exercise, the intensi-
fication process, as well as the engagement in the treat-
ment will be checked during the return to repeat the
appliances; and during the follow-up with the doctor. To
increase adhesion to the intervention protocol, hand-
outs with tables containing dates indicating the days the
patient executes the protocol’s exercises; also with blank
spaces for notes about the use of medication or
occurred complications.
Adjuvant therapies
Both groups will be submitted to the same post interven-
tion care programme, and they will be advised to use
the following adjuvant therapies according to the inten-
sity of their symptoms:
Cryotherapy
Every patient will be oriented to perform cold com-
presses on the tendon insertional region three times a
day, during 20 min, with at least 2 hours of interval
between them.
Painkillers
Level 1:
▸ Dipyrone 1g every 6 hours, in case of pain, or
▸ Paracetamol 750 mg every 6 hours
Level 2 (in case the pain does not diminish with level 1):
▸ Tramadol 50 mg every 6 hours, in case of pain, or
▸ Codeine 30 mg every 6 hours, in case of pain.
The patient must present, at each visit to the doctor,
the daily annotation concerning the used sedative medi-
cation. In case the pain increases right after any of the
established treatments, the patient will be permitted to
take analgesics (group 1) during a period of 5 days. The
medication will be supplied to the patient after the inter-
vention, with the respective orientation concerning its
use. After the period of 5 days of sedation, in case the
pain persists, the patient will be reassessed, to check the
necessity of changing the medication (group 2). If after
the second assessment (with 6 weeks) the pain is stronger
than in the initial painful stage (prior to the treatment),
the patient will have the option of either changing the
treatment or being excluded from the study.
Primary outcome
▸ Visa-A Score
Significant increase in the studied group’s score in com-
parison to the preintervention scores.
Secondary outcome
▸ Visual Analogue Scale
▸ American Orthopedic Foot and Ankle Society scale
▸ Foot and Ankle Outcome Score
▸ Short Form Health Survey 12-item
▸ Algometry (pain threshold and visual analogue scale
with 3 kg)
Participant discontinuation
Participants may be discontinued from the study partici-
pation at any time. Reasons for discontinuation include:
1. Voluntary discontinuation by the participant without
prejudice to further treatment.
2. Development of complex regional pain syndrome or
any huge inflammatory response. Achilles tendon
rupture (all of them are going to be considered failure).
3. Pain and function severe impairment.
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Strategies to increase adhesion to intervention protocols
Handouts with tables containing dates indicating the
days the patient executes the protocol’s exercises and
also having blank spaces for notes about the use of
medication or occurred complications.
Statistical analysis
Primary analysis will be performed on the intention-
to-treat population (all participants with at least one
study intervention and one postbaseline efficacy assess-
ment). The primary point for analyses of efficacy will be
week 24. The Mixed-Model for Repeated Measures
method will be used to impute missing data for partici-
pants who discontinue during the study. The primary
efficacy measure will be change from baseline to study
end point on the Visa-A Score, which will be analysed
with a repeated measures t-test. Subsequently, repeated
measures MANCOVA will be administered to test for
covariations and main effects. The significance level will
be set at a p value <0.05.
DISCUSSION
Insertional Achilles tendinopathy is a common condition,
affecting both athletes and the sedentary population. Its
aetiology is related to a poor biological body response
after micro lesions to the tendon (occurring during train-
ing or in a daily usual activity). Degenerative changes and
a low inflammatory reaction are the characteristics of
these tissues, revealing a low healing response to injury.
This illness normally induces patients to look for medical
care due to pain, function impairment and decrease in
athletic performance. Approximately 16% of the active
individuals end up abandoning their sports activities in
consequence of this disorder.
The traditional initial treatment of choice is non-
surgical, comprehending modalities such as physical
therapy and exercises. Yet this approach has not pro-
duced encouraging results over the past few years, and
currently there is still no standard conservative treatment
for Achilles insertional tendinopathy. Whereas the
eccentric strengthening programme is one of the clini-
cians’ preferred modalities of treatment, it has not led
to the same good results as in other tendon locations.
This scenario contributed to the increase in the number
of surgeries performed for this illness in the past few
decades. Procedures commonly associated to high costs
and possible complications, such as wound dehiscence,
infection, nerve damage and tendon rupture.
Several alternatives to the classical treatment (eg, infiltra-
tion, electrostimulation, sclerotherapy, among others) have
been considered, in order to stimulate healing stimulus to
the degenerated tendon. The low success rates have pro-
vided the impetus to explore practical and cheaper ways
to induce adequate reparation conditions. By stimulating
soft tissue healing by angiogenesis enhancing and diffu-
sion of cytokine molecules, the shock wave therapy has
become a reliable option in the treatment of this illness.
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While isolated shock wave treatment has shown encour-
aging results during the past years, they were not defini-
tive. Adjuvant administration of the Alfredson protocol
proved to be a trustworthy combination in the non-
insertional presentation of this disorder in a recent study.
The technical composition of shock wave and tendon’s
eccentric strengthening can be the answer to the patient’s
improvement in the Achilles insertional tendinopathy,
with the additional benefit of avoiding the complications
and high costs associated with the surgical treatment.
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